Mirabegron Glenmark (Mirabegron)

Mirabegron is a β3‑adrenergic receptor agonist used in the management of overactive bladder.

• Overactive bladder: Increases functional bladder capacity, leading to fewer urgency episodes and reduced urge incontinence.
• Urinary urgency: Diminishes the intensity and frequency of sudden urges to void, improving patient control.
• Urinary frequency: Reduces the number of daytime voids, helping to normalize voiding patterns.
• Urge incontinence: Helps decrease involuntary leakage associated with sudden urges.

• Mirabegron selectively stimulates β3‑adrenergic receptors located in the detrusor smooth muscle of the urinary bladder. Activation of these receptors triggers cyclic AMP accumulation, leading to relaxation of the detrusor muscle during the storage phase. This relaxation increases bladder capacity and reduces involuntary contractions, thereby alleviating symptoms of urgency, frequency, and urge incontinence associated with overactive bladder.

Adverse reactions reported with Mirabegron Glenmark are generally mild to moderate, but serious events can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypertension: increase in blood pressure.
• Nasopharyngitis: upper respiratory tract infection symptoms.
• Constipation: reduced bowel movements.
• Dry mouth: decreased salivation.

Serious or Rare Side Effects

• Urinary retention: difficulty emptying bladder.
• Tachycardia: elevated heart rate.
• Angioedema: swelling of face, lips, or airway.
• Severe hypertension: markedly high blood pressure.
• Acute renal failure: sudden loss of kidney function.

Before initiating therapy with Mirabegron Glenmark, consider the following precautions.

• Blood pressure monitoring: check baseline and periodically during treatment.
• Cardiovascular disease: use cautiously in patients with known heart conditions.
• Drug interactions: review concomitant medications that affect blood pressure or CYP2D6.
• Renal impairment: adjust use in patients with severe renal dysfunction.
• Hepatic impairment: assess liver function before starting therapy.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mirabegron can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors: may increase Mirabegron exposure (e.g., paroxetine, fluoxetine).
• Antihypertensives: additive blood pressure‑lowering effect (e.g., ACE inhibitors, ARBs).

Moderate Interactions (Monitor Closely)

• Anticholinergics: may reduce efficacy of Mirabegron on bladder symptoms.
• Diuretics: potential for increased blood pressure fluctuations.
• Warfarin: monitor INR as Mirabegron may alter anticoagulant effect.